Active	Status	Sponsor type	Region	Phase	Filter
23 Active 20 Inactive 43 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

12 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lee, Eun Bong
Aladdin, NCT04618640: To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years	Recruiting	3	249	RoW	DTaP-IPV combination vaccine	Boryung Biopharma Co., Ltd.	Diphtheria, Tetanus, Pertussis, Poliomyelitis	12/20	07/21
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer	Active, not recruiting	3	291	Europe, Canada, Japan, US, RoW	Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib	Loxo Oncology, Inc., Eli Lilly and Company	Medullary Thyroid Cancer	05/23	02/26
NCT05317858: Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets	Recruiting	3	20	Canada, US, RoW	Blood Brain Barrier Disruption - Oncology, Exablate BBBD, Pembrolizumab	InSightec	Brain Tumor	06/24	12/24
NCT05757102: A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma	Recruiting	3	292	US, RoW	FF/UMEC/VI, ELLIPTA, FF/VI	GlaxoSmithKline	Asthma	01/27	01/27
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis	Active, not recruiting	3	597	Europe, RoW	Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer	United Therapeutics	Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease	07/25	07/25
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis	Recruiting	3	60	Europe, Canada, Japan, US, RoW	Mirikizumab IV, LY3074828, Mirikizumab SC	Eli Lilly and Company	Ulcerative Colitis	07/26	03/27
OPTIMAL, NCT03315364 / 2020-000954-86: Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy	Active, not recruiting	2/3	549	Europe, RoW	Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol®	Daehwa Pharmaceutical Co., Ltd., Daehwa pharmaceutical Co., Ltd.	Recurrent or Metastatic Breast Cancer	02/24	12/25
NAVIGATE, NCT04365868 / 2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis	Active, not recruiting	2b	357	Europe, Canada, US, RoW	belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo	Galectin Therapeutics Inc., Galectin Therapeutics Inc	Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis	12/24	12/24
NCT05032066: A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis	Terminated	2	153	Europe, Canada, Japan, US, RoW	HZN-825, Placebo	Amgen	Idiopathic Pulmonary Fibrosis	07/24	01/25
AFFINITY, NCT04573920: Atrasentan in Patients With Proteinuric Glomerular Diseases	Active, not recruiting	2	103	Europe, US, RoW	Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627	Novartis Pharmaceuticals	IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy	07/24	07/26
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE) Oct 2024 - Dec 2024 : Data for SLE Jul 2024 - Sep 2024 : Data for CLE	Completed	2	456	Europe, Japan, US, RoW	Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Systemic Lupus Erythematosus	11/24	11/24
BBT877-IPF-004, NCT05483907: To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients with IPF Jul 2023 - Dec 2023 : Interim data for the treatment of IPF Initiation of trial in idiopathic pulmonary fibrosis Nov 2022 - Nov 2022: Initiation of trial in idiopathic pulmonary fibrosis	Active, not recruiting	2	129	Europe, US, RoW	BBT-877, Placebo	Bridge Biotherapeutics, Inc.	Idiopathic Pulmonary Fibrosis	01/25	09/25